Extra corporations want to be a part of the burgeoning renal denervation market, with Israeli startup SoniVie finishing enrolment in a pilot examine for its TIVUS (therapeutic intra-vascular ultrasound) system.
The REDUCED-1 pilot (NCT05372679), which is being performed throughout the US and Israel, has enrolled two cohorts of sufferers with uncontrolled stage 2 hypertension. The corporate enrolled 25 sufferers within the US and 15 in Israel.
Headquartered in Tel Aviv, Israel, SoniVie mentioned that each one examine individuals are within the follow-up section of the examine. The trial’s main outcomes are the incidence of hostile occasions and the discount in daytime ambulatory imply systolic blood strain, the latter measured three months after the process.
The renal denervation sector burst into life when ReCor Medical secured the first approval for its Paradise system in November 2023. Medtronic adopted quickly after with clearance for its Symplicity Spyral. Whereas Medtronic’s machine makes use of radiofrequency, ReCor’s system utilises ultrasound, as does SoniVie with its TIVUS know-how.
SoniVie’s CEO Tomaso Zambelli mentioned: “Our subsequent dedication in direction of sufferers, physicians and regulators is now to clinically validate the TIVUS System in a world pivotal trial and broaden its use below the pivotal examine with radial entry procedures.”
Renal denervation includes radiofrequency or ultrasound ablation of afferent and efferent nerves positioned within the renal artery that carry essential alerts to the mind that management blood strain. Decreasing the performance of those pathways results in varied blood pressure-lowering mechanisms. It’s a remedy possibility for sufferers who don’t reply to blood pressure-lowering medication.
Entry essentially the most complete Firm Profiles
in the marketplace, powered by GlobalData. Save hours of analysis. Achieve aggressive edge.
Firm Profile – free
Your obtain electronic mail will arrive shortly
We’re assured in regards to the
high quality of our Firm Profiles. Nonetheless, we would like you to take advantage of
determination for what you are promoting, so we provide a free pattern that you would be able to obtain by
submitting the beneath type
SoniVie is exploring the usage of its know-how past renal artery denervation for resistant hypertension. It has programmes for pulmonary artery denervation for pulmonary hypertension and whole lung denervation for persistent obstructive pulmonary illness with persistent bronchitis.
In December 2023, US-based Ablative introduced that its alcohol-mediated renal denervation with the Peregrine System Equipment achieved the primary endpoint in a Section III trial.
A report by GlobalData estimates the renal denervation catheter market shall be price $533m by 2033, rising at a CAGR of 26% between 2023 after which.